| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 944 | 2018 |
| BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437, 2017 | 476 | 2017 |
| Hypertension and incident cardiovascular events following ibrutinib initiation T Dickerson, T Wiczer, A Waller, J Philippon, K Porter, D Haddad, A Guha, ... Blood, the Journal of the American Society of Hematology 134 (22), 1919-1928, 2019 | 209 | 2019 |
| Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib TE Wiczer, LB Levine, J Brumbaugh, J Coggins, Q Zhao, AS Ruppert, ... Blood advances 1 (20), 1739-1748, 2017 | 155 | 2017 |
| The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation SD Reiff, R Mantel, LL Smith, JT Greene, EM Muhowski, CA Fabian, ... Cancer discovery 8 (10), 1300-1315, 2018 | 145 | 2018 |
| Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia KA Rogers, Y Huang, AS Ruppert, FT Awan, NA Heerema, C Hoffman, ... Blood, The Journal of the American Society of Hematology 132 (15), 1568-1572, 2018 | 102 | 2018 |
| Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia KA Rogers, AS Ruppert, A Bingman, LA Andritsos, FT Awan, KA Blum, ... Leukemia 30 (2), 346-350, 2016 | 98 | 2016 |
| Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia KA Rogers, Y Huang, AS Ruppert, LV Abruzzo, BL Andersen, FT Awan, ... Journal of Clinical Oncology 38 (31), 3626, 2020 | 87 | 2020 |
| Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations J Woyach, Y Huang, K Rogers, SA Bhat, MR Grever, A Lozanski, ... Blood 134, 504, 2019 | 86 | 2019 |
| Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia IW Flinn, JG Gribben, MJS Dyer, W Wierda, MB Maris, RR Furman, ... Blood, The Journal of the American Society of Hematology 133 (26), 2765-2775, 2019 | 83 | 2019 |
| Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies KA Rogers, L Mousa, Q Zhao, SA Bhat, JC Byrd, Z El Boghdadly, ... Leukemia 33 (10), 2527-2530, 2019 | 79 | 2019 |
| Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia JA Woyach, JS Blachly, KA Rogers, SA Bhat, M Jianfar, G Lozanski, ... Cancer discovery 10 (3), 394-405, 2020 | 78 | 2020 |
| A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as … KA Rogers, Y Huang, AS Ruppert, G Salem, DM Stephens, NA Heerema, ... British journal of haematology 180 (2), 259-266, 2018 | 71 | 2018 |
| Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia KA Rogers, PA Thompson, JN Allan, M Coleman, JP Sharman, ... Haematologica 106 (9), 2364, 2021 | 70 | 2021 |
| Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ... Blood advances 4 (19), 4648-4652, 2020 | 68 | 2020 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Second cancer incidence in CLL patients receiving BTK inhibitors DA Bond, Y Huang, JL Fisher, AS Ruppert, DH Owen, EM Bertino, ... Leukemia 34 (12), 3197-3205, 2020 | 59 | 2020 |
| Phase 2 study of ibrutinib in classic and variant hairy cell leukemia KA Rogers, LA Andritsos, L Wei, EM McLaughlin, AS Ruppert, ... Blood, The Journal of the American Society of Hematology 137 (25), 3473-3483, 2021 | 57 | 2021 |
| Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib EM McWilliams, CR Lucas, T Chen, BK Harrington, R Wasmuth, ... Blood advances 3 (3), 447-460, 2019 | 55 | 2019 |
| Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations F Lucas, K Larkin, CT Gregory, S Orwick, TJ Doong, A Lozanski, ... Blood, The Journal of the American Society of Hematology 135 (24), 2192-2195, 2020 | 48 | 2020 |
